MOTS-c

MOTS-c begins its life in an unusual location: the mitochondrial 12S rRNA locus, a stretch of the mitochondrial genome not previously thought to encode functional peptides. When mitochondria detect metabolic stress — elevated AMP/ATP ratio, nutrient restriction, or high-intensity exercise — MOTS-c transcription increases. The peptide is exported to the cytoplasm and, uniquely among mitochondrial-derived peptides, translocates directly to the nucleus, where it modulates the expression of genes governing energy metabolism, antioxidant defence, and stress response. The primary downstream target is **AMPK (AMP-activated protein kinase)** — the master metabolic switch that governs energy homeostasis in virtually every cell type. AMPK activation by MOTS-c triggers a coordinated cascade: inhibition of fatty acid synthesis, promotion of beta-oxidation (fat burning), increased GLUT4 transporter expression on skeletal muscle cell membranes for **insulin-independent glucose uptake**, and upregulation of **PGC-1α** — the master regulator of mitochondrial biogenesis. The net result is a shift toward oxidative fuel use and an increase in cellular energy-handling capacity, mimicking the adaptive metabolic response to endurance exercise without requiring it. A second mechanism distinguishes MOTS-c from pharmacological AMPK activators like AICAR. MOTS-c modulates **one-carbon metabolism and the folate cycle**, diverting folate intermediates away from the de novo purine synthesis pathway toward reactions that support NAD⁺ production and cellular redox balance. AICAR activates AMPK through purine intermediate accumulation — which works, but also generates hepatotoxicity concerns. MOTS-c sidesteps this entirely. Both compounds activate AMPK; only one does it without the liver liability. For practical research protocols, this distinction is the reason MOTS-c is increasingly preferred over AICAR for extended metabolic modulation cycles.